{
    "Clinical Trial ID": "NCT02104830",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Empegfilgrastim 6 mg",
        "  Patients will receive a single administration of empegfilgrastim at a dose of 6 mg subcutaneously , 24 h after the chemotherapy",
        "  Placebo \u21162: Placebo \u21162 should be administered no earlier than 24 hours after the administration of cytotoxic chemotherapy. Placebo \u21162 is supplied as solution for injection 0.0083 ml/kg.",
        "INTERVENTION 2: ",
        "  Empegfilgrastim 7.5 mg",
        "  Patients will receive a single administration of empegfilgrastim at a dose of 7.5 mg subcutaneously, 24 h after the chemotherapy",
        "  Placebo \u21162: Placebo \u21162 should be administered no earlier than 24 hours after the administration of cytotoxic chemotherapy. Placebo \u21162 is supplied as solution for injection 0.0083 ml/kg."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Signed informed consent form;",
        "  Histologically verified diagnosis of stage IIb/III/IV breast cancer;",
        "  Age of 18-70 years inclusive;",
        "  Life expectancy of at least 6 months after inclusion in the study;",
        "  If the patient had received the chemotherapy for breast cancer, it should be finished 30 days before the beginning of the study;",
        "  ECOG Performance Status of 0- 2, not increasing within during 2 weeks before randomization;",
        "  ANC level of 1500/\u03bcL and more at the beginning of the study",
        "  Platelet count of 100 000/\u03bcL and more at the beginning of the study",
        "  Hemoglobin level of 90 g/l and more",
        "  Creatinine level <1.5 mg/dl",
        "  Total bilirubin level <1.5 \u00d7 the upper limit of normal (ULN)",
        "  ALT and/or AST levels <2.5\u00d7ULN (5\u00d7ULN for patients with liver metastases);",
        "  Alkaline phosphatase <5\u00d7ULN;",
        "  Left ventricular ejection fraction >50% and more;",
        "  If the patient had received adjuvant and/or neoadjuvant therapy, the cumulative dose of anthracyclines should not exceed 250 mg/m2 for doxorubicin or 540 mg/m2 for epirubicin,if in this study planned 6 cycles of chemotherapy ;",
        "  If the patient had received adjuvant and/or neoadjuvant therapy, the cumulative dose of anthracyclines should not exceed 350 mg/m2 for doxorubicin or 660 mg/m2 for epirubicin,if in this study planned 4 cycles of chemotherapy ;",
        "  Ability of the participant to follow the protocol requirements, according to the Investigator's opinion;",
        "  Patients of childbearing potential must implement reliable contraceptive measures during the study treatment, starting 4 weeks prior randomization and for 6 months after the last administration of the study drug;",
        "  Patients should be able to follow the Protocol procedures (according to Investigator's assessment.",
        "Exclusion Criteria:",
        "  Patient has received two or more chemotherapy regimens for the metastatic breast cancer;",
        "  Documented hypersensitivity to filgrastim, pegfilgrastim, docetaxel, doxorubicin, dexamethasone and/or its excipients, PEGylated drugs, recombinant proteins.",
        "  Pregnancy or breastfeeding;",
        "  Systemic antibiotic therapy within 72 h prior empegfilgrastim/filgrastim administration;",
        "  Concomitant radiotherapy (except selective radiotherapy of bone metastases);",
        "  Surgery, radiotherapy (except selective radiotherapy of bone metastases), administration of any experimental drugs within 30 days prior randomization;",
        "  History of bone marrow/stem cell transplantation;",
        "  Conditions limiting the patient's ability to follow the protocol;",
        "  CTCAE grade 3-4 neuropathy;",
        "  HIV, HCV, HBV, T.Pallidum infection(s);",
        "  Acute or active chronic infections;",
        "  Severe concurrent diseases (for example, severe arterial hypertension, severe heart failure, and other);",
        "  Severe depression, schizophrenia, any other mental disorders;",
        "  Obstacles in intravenous administration of study drugs;",
        "  Simultaneous participation in other clinical trials, previous participation in other clinical trials within 30 days before entering into the trial, previous participation in the same trial."
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Duration of Neutropenia CTCAE Grade 4",
        "  The primary endpoint, which will allow to compare the efficacy of the single dose of Extimia\u00ae versus nonpegylated daily filgrastim is the number of breast cancer patients developing CTCAE grade 3/4 neutropenia after the first AT chemotherapy cycle (doxorubicin+docetaxel).",
        "  Time frame: 3 weeks",
        "Results 1: ",
        "  Arm/Group Title: Empegfilgrastim 6 mg",
        "  Arm/Group Description: Patients will receive a single administration of empegfilgrastim at a dose of 6 mg subcutaneously , 24 h after the chemotherapy",
        "  Placebo \u21162: Placebo \u21162 should be administered no earlier than 24 hours after the administration of cytotoxic chemotherapy. Placebo \u21162 is supplied as solution for injection 0.0083 ml/kg.",
        "  Overall Number of Participants Analyzed: 42",
        "  Mean (Standard Deviation)",
        "  Unit of Measure: days  0.905         (1.206)",
        "Results 2: ",
        "  Arm/Group Title: Empegfilgrastim 7.5 mg",
        "  Arm/Group Description: Patients will receive a single administration of empegfilgrastim at a dose of 7.5 mg subcutaneously, 24 h after the chemotherapy",
        "  Placebo \u21162: Placebo \u21162 should be administered no earlier than 24 hours after the administration of cytotoxic chemotherapy. Placebo \u21162 is supplied as solution for injection 0.0083 ml/kg.",
        "  Overall Number of Participants Analyzed: 43",
        "  Mean (Standard Deviation)",
        "  Unit of Measure: days  0.791         (1.013)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 1/42 (2.38%)",
        "  Febrile neutropenia 0/42 (0.00%)",
        "  Agranulocytosis 0/42 (0.00%)",
        "  nose furunculus 3 grade 0/42 (0.00%)",
        "  Left hand fracture 0/42 (0.00%)",
        "  Uterine bleeding 1/42 (2.38%)",
        "  Pneumonia 0/42 (0.00%)",
        "Adverse Events 2:",
        "  Total: 1/43 (2.33%)",
        "  Febrile neutropenia 1/43 (2.33%)",
        "  Agranulocytosis 0/43 (0.00%)",
        "  nose furunculus 3 grade 0/43 (0.00%)",
        "  Left hand fracture 0/43 (0.00%)",
        "  Uterine bleeding 0/43 (0.00%)",
        "  Pneumonia 0/43 (0.00%)"
    ]
}